|Bid||28.17 x 900|
|Ask||31.19 x 800|
|Day's Range||30.89 - 31.39|
|52 Week Range||19.00 - 38.00|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.00|
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy (IgAN).
Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 pm CET/8:30 am ET. Calliditas will also host 1x1 meetings during the conference. Details for the presentation are as follows:
The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on May 27, 2021.